Betrixaban - Wikipedia
In 2011 Merck discontinued joint development. [ 4 ] The drug has undergone clinical trials for prevention of embolism after knee surgery [ 5 ] and for prevention of stroke following non-valvular atrial fibrillation .
Betrixaban (oral route) - Mayo Clinic
2024年2月1日 · Betrixaban is used to prevent venous thromboembolism (VTE) in hospitalized patients at risk for blood clots because of the loss or decreased ability to move around or due to other factors. Betrixaban is a factor Xa inhibitor, an anticoagulant.
Bevyxxa (betrixaban): Uses, Side Effects, Dosage & Reviews - GoodRx
2021年8月31日 · Bevyxxa (betrixaban) was discontinued and taken off the market in April 2020. It was removed from the market by the manufacturer, Portola, for business reasons. The medication was not discontinued due to safety reasons.
FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis …
The most frequent reason for treatment discontinuation was bleeding, with an incidence rate for all bleeding episodes of 2.4% and 1.2% for betrixaban and enoxaparin, respectively.
Extended Thromboprophylaxis with Betrixaban in Acutely Ill …
2016年5月27日 · In exploratory analyses in our trial, we found that oral betrixaban can be extended after discharge to reduce the rate of venous thromboembolism among patients who are categorized according to ...
Betrixaban: Indications, Side Effects, Warnings - Drugs.com
2024年2月25日 · Read it again each time betrixaban is refilled. If you have any questions about betrixaban, please talk with the doctor, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away.
Bevyxxa: Uses, Dosage, Side Effects & Warnings - Drugs.com
2024年9月30日 · Bevyxxa (betrixaban) blocks the activity of certain clotting substances in the blood. Bevyxxa is used to prevent blood clots in adults who have a serious illness and decreased ability to move. Includes uses, side effects, interactions, warnings and more..
Bevyxxa (betrixaban) FDA Approval History - Drugs.com
2017年6月23日 · FDA Approved: Yes (First approved June 23, 2017) Brand name: Bevyxxa. Generic name: betrixaban. Dosage form: Capsules. Company: Portola Pharmaceuticals, Inc. Treatment for: Prevention of Venous Thromboembolism.
Formulary Drug Review: Betrixaban - PMC - National Center for ...
Betrixaban is the only oral factor Xa inhibitor approved for this indication. The recommended duration of treatment with betrixaban is 35 to 42 days. Because betrixaban is not a CYP3A4 substrate, the risk of certain drug-drug interactions with betrixaban is decreased.
Betrixaban: A Novel Oral Anticoagulant With a New Niche
2018年2月26日 · Betrixaban is the first direct oral anticoagulant approved for VTE prophylaxis in adult, acutely ill patients at risk for thromboembolisms. Based on the APEX trial, betrixaban 80 mg administered daily for 35 to 42 days was compared to enoxaparin administered daily for 6 …
- 某些结果已被删除